Literature DB >> 10717168

Medically Inoperable Lung Carcinoma: The Role of Radiation Therapy.

.   

Abstract

Although surgery has traditionally been the treatment of choice for patients with resectable non-small cell lung cancer, for those with significant medical problems where surgery is contraindicated, radiation therapy (RT) is a reasonable treatment modality. In contrast to the widely held belief that RT confers little benefit to these patients, a review of the literature and our own series of 245 patients shows that RT can provide significant tumor shrinkage, improved symptoms, and in a small but not negligible number of patients, cure. Several prognostic factors have emerged, including patient performance status, prior weight loss, tumor size, and radiation dose. Patients with a good performance status and a small tumor treated to a dose of 65 Gy or more have a real possibility of long-term survival and cure. Larger tumors demand strategies to improve the therapeutic ratio, such as hyperfractionation, conformal RT, brachytherapy boosts, or chemotherapy. Patients with medically inoperable lung cancer should be offered RT with curative intent, rather than the option of no treatment.

Entities:  

Year:  1996        PMID: 10717168     DOI: 10.1053/SRAO00600098

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  23 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  A method for improved verification of entire IMRT plans by film dosimetry.

Authors:  Vesna Jacob; Peter Kneschaurek
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

3.  Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer.

Authors:  C B Falkson; E T Vella; E Yu; M El-Mallah; R Mackenzie; P M Ellis; Y C Ung
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

4.  An orthotopic lung tumor model for image-guided microirradiation in rats.

Authors:  Debabrata Saha; Linda Watkins; Yi Yin; Philip Thorpe; Michael D Story; Kwang Song; Pavithra Raghavan; Robert Timmerman; Benjamin Chen; John D Minna; Timothy D Solberg
Journal:  Radiat Res       Date:  2010-07       Impact factor: 2.841

Review 5.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review.

Authors:  N P Rowell; C J Williams
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

6.  Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer.

Authors:  Meritxell Mollà; Jordi Saez; Monica Ramos; Alexandra Giraldo; Alejandro Seoane; Jordi Andreu; Marc Simó; Jordi Giralt
Journal:  Br J Radiol       Date:  2016-03-17       Impact factor: 3.039

Review 7.  Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

Authors:  Robert D Timmerman; Joseph Herman; L Chinsoo Cho
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

8.  Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.

Authors:  T Yung; M E Giuliani; L W Le; A Sun; B C J Cho; A Bezjak; A Brade; A J Hope
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

9.  Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).

Authors:  Donata von Reibnitz; Fauzia Shaikh; Abraham J Wu; Gregory C Treharne; Rosalind Dick-Godfrey; Amanda Foster; Kaitlin M Woo; Weiji Shi; Zhigang Zhang; Shaun U Din; Daphna Y Gelblum; Ellen D Yorke; Kenneth E Rosenzweig; Andreas Rimner
Journal:  Acta Oncol       Date:  2018-06-06       Impact factor: 4.089

Review 10.  Inoperable localized stage I and stage II non-small-cell lung cancer.

Authors:  Eric L Gressen; Walter J Curran
Journal:  Curr Treat Options Oncol       Date:  2002-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.